What You Should Know:
– Cardiopulmonary digital health company Eko raises $65M in Series C funding to close the gap between virtual and in-person heart and lung care.
– The latest round of funding will enable Eko to expand in-clinic use of its platform of telehealth and AI algorithms for disease screening and to launch a monitoring program for cardiopulmonary patients at home.
Eko, a cardiopulmonary digital health company, today announced $65 million in Series C funding led by Highland Capital Partners and Questa Capital, with participation from Artis Ventures, DigiTx Partners, NTTVC, 3M Ventures, and other new and existing investors. The new funding will be used to expand in-clinic use of the company’s platform of telehealth and AI algorithms for disease screening, and to launch a monitoring program for cardiopulmonary patients at home.
Eko was founded in 2013 to improve heart and lung care for patients through advanced sensors, digital technology, and novel AI algorithms. The company reinvented the stethoscope and introduced the first combined handheld digital stethoscope and electrocardiogram (ECG). Eko’s FDA-cleared AI analysis algorithms help detect heart rhythm abnormalities and structural heart disease. Eko seeks to make AI analysis the standard for every physical exam. The company recently launched Eko AI and Eko Telehealth to combat the needs of the COVID-19 pandemic.
Eko Telehealth delivers:
– AI-powered and FDA-cleared identification of heart murmurs and atrial fibrillation (AFib), assisting providers in the detection and monitoring of heart disease during virtual visits
– Lung and heart sound live-streaming for a thorough virtual examination
– Single-lead ECG live-streaming, enabling providers to assess for rhythm abnormalities
– Embedded HIPAA-compliant video conferencing, or can work alongside the video conferencing platform a health system has in place
Symptoms of valvular heart disease and AFib often go undiagnosed during routine physical exams. With the development of Eko’s AI screening algorithms, clinicians are able to harness state-of-the-art machine learning to detect heart disease at the earliest point of care regardless if the patient visit is in-person or remote.
“We are thrilled that our new investors have joined our journey and our existing investors have reaffirmed their support for Eko,” said Connor Landgraf, CEO and co-founder at Eko. “The explosion in demand for virtual cardiac and pulmonary care has driven Eko’s rapid expansion at thousands of hospitals and healthcare facilities, and we are excited for how this funding will accelerate the growth of our cardiopulmonary platform.”
